Mind Medicine (MindMed) (MNMD) Projected to Post Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMD) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.36) per share for the quarter.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period last year, the firm posted ($0.59) earnings per share. On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Trading Down 3.6 %

Shares of MNMD opened at $6.32 on Wednesday. Mind Medicine has a 12-month low of $4.70 and a 12-month high of $10.44. The firm has a market capitalization of $475.95 million, a P/E ratio of -2.79 and a beta of 2.52. The firm has a 50-day moving average price of $6.12 and a 200 day moving average price of $6.95. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insider Activity

In related news, insider Daniel Karlin sold 6,836 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the completion of the transaction, the insider now directly owns 446,177 shares in the company, valued at $3,007,232.98. This trade represents a 1.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert Barrow sold 21,208 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $142,941.92. Following the sale, the chief executive officer now owns 856,556 shares in the company, valued at $5,773,187.44. This trade represents a 2.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,391 shares of company stock valued at $204,835. 2.26% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MNMD. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Mind Medicine (MindMed) in a research note on Friday, March 7th. Evercore ISI assumed coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Robert W. Baird reduced their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Ten analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Mind Medicine (MindMed) presently has an average rating of “Buy” and an average target price of $25.11.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.